The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC).
Naiyer A. Rizvi
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb; MedImmune; Roche/Genentech
Laura Quan Man Chow
No relevant relationships to disclose
Luc Yves Dirix
No relevant relationships to disclose
Scott N. Gettinger
No relevant relationships to disclose
Michael S. Gordon
Consultant or Advisory Role - Genentech
Research Funding - Roche/Genentech
Fairooz F. Kabbinavar
Honoraria - Roche
Joachim Von Pawel
Consultant or Advisory Role - Clovis; Daiichi Sankyo; Pfizer; Vertex
Jean-Charles Soria
Honoraria - Roche/Genentech
Colombe Chappey
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Ahmad Mokatrin
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche/Genentech
Alan Sandler
Employment or Leadership Position - Roche/Genentech
Consultant or Advisory Role - Roche/Genentech
Stock Ownership - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech
Expert Testimony - Roche/Genentech
Daniel Waterkamp
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
David R. Spigel
Consultant or Advisory Role - Genentech (U)